Forget Pure-Play Quantum Computing Stocks. These 2 Beaten-Down Giants May Be the Smarter Bet

IBM reported Q4 2025 revenue growth of 12% YoY, an AI book of business of $12.5B (up from $5B a year ago) and nearly $15B in free cash flow last year; the stock is down >20% YTD in 2026. Zscaler grew revenue 26% YoY in its most recent quarter and the share price sits roughly 60% below its 52-week high; the company is positioning for post-quantum cryptography demand. Both names offer quantum-computing exposure but have diversified, multi-billion-dollar business lines that support the investment thesis if quantum commercialization is delayed.

Analysis

IBM’s scale and free-cash flexibility create a non-obvious barrier to entry in quantum: beyond building qubits, it can vertically integrate software stacks, certification services, and enterprise migration projects, turning quantum R&D into recurring services that squeeze pure-play valuations. That consolidation will concentrate demand into a smaller set of suppliers for control electronics, cryogenics, and specialized fab runs—benefitting large incumbents that can offer end-to-end procurement instead of point-solution startups.

Zscaler sits at the other end of the chain: post-quantum cryptography is less a single-product win and more a multi-year migration tax on enterprises, creating predictable multi-quarter consulting and enforcement spend as firms inventory keys and re-certify systems. The pace of that spend will be governed by standards and procurement cycles (NIST-like approvals, large ERP/cloud refreshes), so headline shocks (e.g., a breakthrough demonstrating crypto breakability) would accelerate budgets; conversely, steady standardization without urgency slows revenue recognition into later-year buckets.

Key tail risks: an unexpected algorithmic advance or an open-source quantum stack could invalidate current vendor moats, and AI-driven automation of security policy could compress Zscaler’s incremental margins over 12–24 months. Time horizons split: tactical trading opportunities play out in weeks–months around earnings/standards milestones, whereas the core quantum re-rating is a multi-year arbitrage (3–7+ years) tied to fault-tolerance and enterprise migration cadence.

Key Decisions for Investors

• Long IBM (6–12 months): allocate 1.5% AUM to a 9–12 month 15–25% OTM call spread (buy calls to cap cost, sell higher strike to finance) — target payoff 2.5x premium if IBM posts consecutive execution beats or announces a major enterprise quantum partnership; hard stop: mark-to-market loss of 40% of premium if roadmap misses two consecutive milestones.
• Long ZS (12 months): buy equity or a 9–12 month 20% OTM call (size 1% AUM) to play steady PQC migration and renewals cadence — upside: 30–50% if enterprise adoption accelerates after standards; downside: limit position if churn or gross margin compression emerges beyond 200bps over two quarters.
• Relative-value pair (3–9 months): long IBM / short NVDA, equal notional 0.5% AUM each — directionally captures potential IBM re-rating as quantum/enterprise services decouple from pure AI hardware euphoria; hedge reduces pure AI beta but monitor NVDA catalyst windows (product/earnings) that can widen spread volatility.
• Event/opportunistic shorts (size <0.5% AUM): identify high-valuation, pre-revenue quantum pure-plays after big secondary raises — short or buy put spreads on momentum exhaustions tied to dilution events, aiming for 2–3x option returns within 3–9 months while keeping strict max drawdown per trade at 30%.